UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2019
INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEVADA | | 000-52991 | | 90-0814124 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| |
8845 REHCO ROAD, SAN DIEGO, CA 92121 | | 92121 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (858) 964-5123
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock $0.001 par value | INNV | OTCQB |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 – Other Events
On June 5, 2019, Innovus Pharmaceuticals, Inc., (the “Company”) and Acerus Pharmaceuticals, Inc., (“Acerus”) agreed to mutually terminate their Exclusive Distribution and License Agreement (the “Agreement”) for the Company’s UriVarx® product in Canada. The termination was due to a refocused strategy by Acerus and all rights to market and sell the product in Canada were returned to the Company to sell directly to customers in that country.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | INNOVUS PHARMACEUTICALS, INC. |
| | |
| | By: | | /s/ Randy Berholtz |
| | | | Randy Berholtz Executive Vice President, Corporate Development and General Counsel |
Date: June 5, 2019 | | | | |
